Pub Date : 2026-01-07DOI: 10.1001/jamapsychiatry.2025.4091
Luis F Rivera-Chávez,Daniela González-Sangabriel,Luz González-Manríquez,Tomás Moncada-Habib,Pablo León-Ortiz,Melanie Malacara,Francisco Reyes-Madrigal,Camilo de la Fuente-Sandoval
ImportanceEvidence suggests that elevated glutamate levels in the medial prefrontal cortex may be associated with the illness stage, but little is known about whether these effects occur in the absence of antipsychotic treatment.ObjectiveTo evaluate differences in glutamate levels in treatment-naive individuals with psychosis on the schizophrenia spectrum at different stages of the illness.Design, Setting, and ParticipantsThis cross-sectional study uses proton magnetic resonance spectroscopy in the medial prefrontal cortex of individuals experiencing their first episode of nonaffective psychosis, individuals with chronic schizophrenia, and matched controls at inpatient and outpatient services of the Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico, from November 2017 to July 2025. Data were analyzed from January 28, 2025, to August 8, 2025.ExposureProton magnetic resonance spectroscopy.Main Outcomes and MeasuresThe primary outcome was glutamate levels and scores measured on the Positive and Negative Syndrome Scale for Schizophrenia and the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.ResultsThis cross-sectional study included a total of 181 individuals (65 with first-episode psychosis [FEP], 42 with chronic schizophrenia, and 74 age- and sex-matched healthy controls). Data from 38 participants (14 with FEP, 10 with schizophrenia, and 14 controls) were rejected from all analyses due to excessive movement or poor spectral quality, leaving 83 participants and 60 controls. The mean (SD) age was 25.9 (7.2) years for individuals with FEP, 38.0 (14.5) years for those with chronic schizophrenia, and 30.4 (11.5) years for controls. Sex distribution did not differ (34 male individuals with FEP [67.0%]; 20 male individuals with chronic schizophrenia [62.5%]; and 33 male controls [55.0%]; P = .44). Glutamate levels differed among the 3 groups (F2,136 = 7.5; P = .001). Post hoc pairwise comparisons revealed higher glutamate levels in the FEP group compared with both the chronic schizophrenia group (P = .003; Cohen d = 0.69) and the control group (P = .008; Cohen d = 0.83). There were no significant differences in glutamate levels between the chronic schizophrenia group and the control group (P > .99). Higher glutamate levels were associated with lower verbal (ρ = -0.29; P = .04) and visual learning scores (ρ = -0.29; P = .04) in the FEP group.Conclusions and RelevanceThese findings suggest that the differences in glutamate levels may indicate that these alterations occur primarily in the early stages of the disease. The results of this study have implications for resuming clinical trials with targeted metabotropic glutamate receptor 2/3 agonists, taking into account both the disease phase and the glutamatergic alterations measured by magnetic resonance imaging.
重要证据表明，内侧前额叶皮层谷氨酸水平升高可能与疾病阶段有关，但很少有人知道这些影响是否发生在没有抗精神病药物治疗的情况下。目的评价未接受治疗的精神分裂症患者在不同病程阶段谷氨酸水平的差异。设计、环境和参与者本横断面研究在2017年11月至2025年7月期间，在墨西哥墨西哥城国立研究所Neurología y Neurocirugía的住院和门诊服务中，对首次经历非情感性精神病发作的个体、慢性精神分裂症患者和匹配对照进行了质子磁共振波谱检测。数据分析时间为2025年1月28日至2025年8月8日。质子磁共振光谱学。主要结局和测量主要结局为谷氨酸水平和精神分裂症阳性和阴性综合征量表的评分，以及改善精神分裂症共识认知电池认知的测量和治疗研究。结果本横断面研究共纳入181人（65例首发精神病，42例慢性精神分裂症，74例年龄和性别匹配的健康对照）。38名参与者（14名FEP患者，10名精神分裂症患者和14名对照组）的数据因过度运动或光谱质量差而被所有分析拒绝，剩下83名参与者和60名对照组。FEP患者的平均（SD）年龄为25.9（7.2）岁，慢性精神分裂症患者的平均（SD）年龄为38.0（14.5）岁，对照组为30.4（11.5）岁。性别分布无差异（男性FEP患者34例[67.0%]，男性慢性精神分裂症患者20例[62.5%]，男性对照组33例[55.0%],P = 0.44）。谷氨酸水平在三组间存在差异（f2136 = 7.5; P = 0.001）。事后两两比较显示，FEP组的谷氨酸水平高于慢性精神分裂症组（P = 0.003; Cohen d = 0.69）和对照组（P = 0.008; Cohen d = 0.83）。慢性精神分裂症组与对照组间谷氨酸水平差异无统计学意义（P < 0.05）。较高的谷氨酸水平与较低的言语水平相关(ρ = -0.29; P =。04)和视觉学习分数(ρ = -0.29; P =。04) FEP组。结论和相关性这些发现提示谷氨酸水平的差异可能表明这些改变主要发生在疾病的早期阶段。考虑到疾病阶段和磁共振成像测量的谷氨酸能改变，本研究的结果对恢复靶向代谢型谷氨酸受体2/3激动剂的临床试验具有重要意义。
{"title":"Glutamate Levels in Medial Prefrontal Cortex According to Illness Phase of Never-Medicated Individuals With Psychosis.","authors":"Luis F Rivera-Chávez,Daniela González-Sangabriel,Luz González-Manríquez,Tomás Moncada-Habib,Pablo León-Ortiz,Melanie Malacara,Francisco Reyes-Madrigal,Camilo de la Fuente-Sandoval","doi":"10.1001/jamapsychiatry.2025.4091","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.4091","url":null,"abstract":"ImportanceEvidence suggests that elevated glutamate levels in the medial prefrontal cortex may be associated with the illness stage, but little is known about whether these effects occur in the absence of antipsychotic treatment.ObjectiveTo evaluate differences in glutamate levels in treatment-naive individuals with psychosis on the schizophrenia spectrum at different stages of the illness.Design, Setting, and ParticipantsThis cross-sectional study uses proton magnetic resonance spectroscopy in the medial prefrontal cortex of individuals experiencing their first episode of nonaffective psychosis, individuals with chronic schizophrenia, and matched controls at inpatient and outpatient services of the Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico, from November 2017 to July 2025. Data were analyzed from January 28, 2025, to August 8, 2025.ExposureProton magnetic resonance spectroscopy.Main Outcomes and MeasuresThe primary outcome was glutamate levels and scores measured on the Positive and Negative Syndrome Scale for Schizophrenia and the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.ResultsThis cross-sectional study included a total of 181 individuals (65 with first-episode psychosis [FEP], 42 with chronic schizophrenia, and 74 age- and sex-matched healthy controls). Data from 38 participants (14 with FEP, 10 with schizophrenia, and 14 controls) were rejected from all analyses due to excessive movement or poor spectral quality, leaving 83 participants and 60 controls. The mean (SD) age was 25.9 (7.2) years for individuals with FEP, 38.0 (14.5) years for those with chronic schizophrenia, and 30.4 (11.5) years for controls. Sex distribution did not differ (34 male individuals with FEP [67.0%]; 20 male individuals with chronic schizophrenia [62.5%]; and 33 male controls [55.0%]; P = .44). Glutamate levels differed among the 3 groups (F2,136 = 7.5; P = .001). Post hoc pairwise comparisons revealed higher glutamate levels in the FEP group compared with both the chronic schizophrenia group (P = .003; Cohen d = 0.69) and the control group (P = .008; Cohen d = 0.83). There were no significant differences in glutamate levels between the chronic schizophrenia group and the control group (P > .99). Higher glutamate levels were associated with lower verbal (ρ = -0.29; P = .04) and visual learning scores (ρ = -0.29; P = .04) in the FEP group.Conclusions and RelevanceThese findings suggest that the differences in glutamate levels may indicate that these alterations occur primarily in the early stages of the disease. The results of this study have implications for resuming clinical trials with targeted metabotropic glutamate receptor 2/3 agonists, taking into account both the disease phase and the glutamatergic alterations measured by magnetic resonance imaging.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"2 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamapsychiatry.2025.3242
Ioana A Cristea, Martin Plöderl, Florian Naudet
{"title":"Esketamine for Treatment-Resistant Depression.","authors":"Ioana A Cristea, Martin Plöderl, Florian Naudet","doi":"10.1001/jamapsychiatry.2025.3242","DOIUrl":"10.1001/jamapsychiatry.2025.3242","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"103"},"PeriodicalIF":17.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamapsychiatry.2025.3248
Adam Janik, Richard C Shelton, Dong-Jing Fu
{"title":"Esketamine for Treatment-Resistant Depression-Reply.","authors":"Adam Janik, Richard C Shelton, Dong-Jing Fu","doi":"10.1001/jamapsychiatry.2025.3248","DOIUrl":"10.1001/jamapsychiatry.2025.3248","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"104-105"},"PeriodicalIF":17.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1001/jamapsychiatry.2025.3032
Jack D C Dahan, Jasper B Zantvoord, Anja Lok, Karel W F Scheepstra
{"title":"Overmystifying the Psychedelic Experience.","authors":"Jack D C Dahan, Jasper B Zantvoord, Anja Lok, Karel W F Scheepstra","doi":"10.1001/jamapsychiatry.2025.3032","DOIUrl":"10.1001/jamapsychiatry.2025.3032","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"11-12"},"PeriodicalIF":17.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145389845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1001/jamapsychiatry.2025.3893
Danielle N Pratt,Nashya Linares,Catherine Spencer,Gabrielle M Olson,Maeve Hoffman,Sophia Parmacek,Lauren E Lee,Luz Maria Alliende,Vanessa Zarubin,Dwight Dickinson,James M Gold,Vijay A Mittal
ImportanceCognition is impaired in people with schizophrenia, affecting quality of life and functioning. Therefore, it is important to understand and characterize this impairment.ObjectiveTo update and revisit the evidence for a central processing speed impairment in people with schizophrenia and examine the factors that moderate this impairment.Data SourcesArticles were identified through the PubMed and PsycINFO databases from February 1, 2009, through November 2, 2023.Study SelectionStudies were included if they reported on a symbol coding test and at least 2 additional cognitive tests from 2 other cognitive domains, contrasted people with schizophrenia to controls, used contemporary diagnostic criteria, included sufficient detail to calculate Hedges g effect sizes, and were reported in English. Of 4530 identified articles, 115 studies met inclusion criteria.Data Extraction and SynthesisThis study followed the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. Means, SDs, and sample sizes were extracted for all cognitive tests that appeared in at least 3 of the 115 studies. Data were entered and visually checked by independent extractors. Data were generally pooled using random-effects models, except when specified. Measures of homogeneity (Q and I2) and publication bias (fail-safe N and funnel plots) were also examined.Main Outcomes and MeasuresThe primary outcome was the degree of cognitive impairment (Hedges g) observed for people with schizophrenia in 50 cognitive tests, focusing on symbol coding tests of processing speed. Further, this study aimed to identify clinical and study characteristics that moderate the degree of symbol coding impairment.ResultsData were available for 10 114 people with schizophrenia and 13 235 controls from 115 studies. Symbol coding tasks were among the most impaired (g = -1.52; 95% CI, -1.65 to -1.40) but did not reliably differ from 15 other tests. Intelligence quotient and age difference from controls, composition of sex assigned at birth, inpatient status, and whether the sample included schizoaffective and schizophreniform diagnoses all moderated the degree of symbol coding impairment.Conclusions and RelevanceThis meta-analysis provides insight into the consistency of the processing speed impairment for people with schizophrenia. Findings support that this impairment may be central to global cognitive impairments, which might be a consequence of altered brain connectivity.
{"title":"Processing Speed Impairment in Schizophrenia: An Updated Systematic Review and Meta-Analysis.","authors":"Danielle N Pratt,Nashya Linares,Catherine Spencer,Gabrielle M Olson,Maeve Hoffman,Sophia Parmacek,Lauren E Lee,Luz Maria Alliende,Vanessa Zarubin,Dwight Dickinson,James M Gold,Vijay A Mittal","doi":"10.1001/jamapsychiatry.2025.3893","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.3893","url":null,"abstract":"ImportanceCognition is impaired in people with schizophrenia, affecting quality of life and functioning. Therefore, it is important to understand and characterize this impairment.ObjectiveTo update and revisit the evidence for a central processing speed impairment in people with schizophrenia and examine the factors that moderate this impairment.Data SourcesArticles were identified through the PubMed and PsycINFO databases from February 1, 2009, through November 2, 2023.Study SelectionStudies were included if they reported on a symbol coding test and at least 2 additional cognitive tests from 2 other cognitive domains, contrasted people with schizophrenia to controls, used contemporary diagnostic criteria, included sufficient detail to calculate Hedges g effect sizes, and were reported in English. Of 4530 identified articles, 115 studies met inclusion criteria.Data Extraction and SynthesisThis study followed the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. Means, SDs, and sample sizes were extracted for all cognitive tests that appeared in at least 3 of the 115 studies. Data were entered and visually checked by independent extractors. Data were generally pooled using random-effects models, except when specified. Measures of homogeneity (Q and I2) and publication bias (fail-safe N and funnel plots) were also examined.Main Outcomes and MeasuresThe primary outcome was the degree of cognitive impairment (Hedges g) observed for people with schizophrenia in 50 cognitive tests, focusing on symbol coding tests of processing speed. Further, this study aimed to identify clinical and study characteristics that moderate the degree of symbol coding impairment.ResultsData were available for 10 114 people with schizophrenia and 13 235 controls from 115 studies. Symbol coding tasks were among the most impaired (g = -1.52; 95% CI, -1.65 to -1.40) but did not reliably differ from 15 other tests. Intelligence quotient and age difference from controls, composition of sex assigned at birth, inpatient status, and whether the sample included schizoaffective and schizophreniform diagnoses all moderated the degree of symbol coding impairment.Conclusions and RelevanceThis meta-analysis provides insight into the consistency of the processing speed impairment for people with schizophrenia. Findings support that this impairment may be central to global cognitive impairments, which might be a consequence of altered brain connectivity.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"38 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1001/jamapsychiatry.2025.4262
Gang Wang,Matthew A Spear,Wen Luo
{"title":"Restricting Liafensine on the Basis of ANK3 Genotype-More Evidence Needed-Reply.","authors":"Gang Wang,Matthew A Spear,Wen Luo","doi":"10.1001/jamapsychiatry.2025.4262","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.4262","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"28 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1001/jamapsychiatry.2025.3874
Kelly Fung,Loreen Straub,Brian T Bateman,Sonia Hernandez-Diaz,Gregory Brill,Yanmin Zhu,Lee S Cohen,Kathryn J Gray,Krista F Huybrechts
ImportanceSleep disturbances are common in pregnancy and often treated with nonbenzodiazepine sedative hypnotics (Z-drugs). However, there is limited evidence on the fetal safety of Z-drugs.ObjectiveTo evaluate whether Z-drug exposure in the first trimester of pregnancy is associated with an increased risk of congenital malformations.Design, Setting, and ParticipantsThis US population-based cohort study evaluated health care utilization data from publicly insured beneficiaries in the Medicaid database (2000-2018) and commercially insured beneficiaries in the Merative MarketScan database (2003-2020). Participants were pregnant individuals and their liveborn infants, with maternal enrollment from 90 days before pregnancy to 30 days after delivery and infant enrollment for 90 days after birth unless death occurred sooner. Data analysis was performed from November 2023 to April 2025.ExposureAt least 1 dispensing of Z-drugs (zaleplon, eszopiclone, or zolpidem) in the first trimester of pregnancy compared with no dispensing.Main Outcomes and MeasuresMajor congenital malformations were identified using linked maternal and infant claims. The risks of any major congenital malformation, organ-specific malformations, and individual malformations in pregnancies with Z-drug exposure in the first trimester were compared with the risks in unexposed pregnancies. Relative risks (RRs) and 95% CIs were estimated. Propensity score fine stratification weights were used to control for confounders.ResultsA total of 4 281 579 pregnancies were identified (mean [SD] maternal age at delivery, 25.2 [6.0] years in Medicaid and 31.6 [4.6] years in MarketScan). First-trimester Z-drug exposure was identified in 11 652 (0.5%) of 2 506 106 pregnancies in Medicaid and 10 862 (0.6%) of 1 775 473 pregnancies in MarketScan; 92.1% of exposed pregnancies had zolpidem exposure. The adjusted pooled RR for malformations overall was 1.01 (95% CI, 0.95-1.08). While adjusted pooled RRs were increased for abdominal wall defects (1.46; 95% CI, 0.89-2.38), tetralogy of Fallot (1.45; 95% CI, 0.86-2.46), and neural tube defects (1.62; 95% CI, 0.96-2.74), these associations were imprecisely estimated, driven by the Medicaid cohort and not replicated in the MarketScan cohort. Results were consistent across multiple sensitivity analyses.Conclusions and RelevanceThese findings suggest that Z-drug exposure in the first trimester of pregnancy is not associated with a meaningful elevation in the risk of congenital malformations overall, nor was there a consistent signal observed for organ-specific or uncommon, individual malformations examined.
{"title":"Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations.","authors":"Kelly Fung,Loreen Straub,Brian T Bateman,Sonia Hernandez-Diaz,Gregory Brill,Yanmin Zhu,Lee S Cohen,Kathryn J Gray,Krista F Huybrechts","doi":"10.1001/jamapsychiatry.2025.3874","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.3874","url":null,"abstract":"ImportanceSleep disturbances are common in pregnancy and often treated with nonbenzodiazepine sedative hypnotics (Z-drugs). However, there is limited evidence on the fetal safety of Z-drugs.ObjectiveTo evaluate whether Z-drug exposure in the first trimester of pregnancy is associated with an increased risk of congenital malformations.Design, Setting, and ParticipantsThis US population-based cohort study evaluated health care utilization data from publicly insured beneficiaries in the Medicaid database (2000-2018) and commercially insured beneficiaries in the Merative MarketScan database (2003-2020). Participants were pregnant individuals and their liveborn infants, with maternal enrollment from 90 days before pregnancy to 30 days after delivery and infant enrollment for 90 days after birth unless death occurred sooner. Data analysis was performed from November 2023 to April 2025.ExposureAt least 1 dispensing of Z-drugs (zaleplon, eszopiclone, or zolpidem) in the first trimester of pregnancy compared with no dispensing.Main Outcomes and MeasuresMajor congenital malformations were identified using linked maternal and infant claims. The risks of any major congenital malformation, organ-specific malformations, and individual malformations in pregnancies with Z-drug exposure in the first trimester were compared with the risks in unexposed pregnancies. Relative risks (RRs) and 95% CIs were estimated. Propensity score fine stratification weights were used to control for confounders.ResultsA total of 4 281 579 pregnancies were identified (mean [SD] maternal age at delivery, 25.2 [6.0] years in Medicaid and 31.6 [4.6] years in MarketScan). First-trimester Z-drug exposure was identified in 11 652 (0.5%) of 2 506 106 pregnancies in Medicaid and 10 862 (0.6%) of 1 775 473 pregnancies in MarketScan; 92.1% of exposed pregnancies had zolpidem exposure. The adjusted pooled RR for malformations overall was 1.01 (95% CI, 0.95-1.08). While adjusted pooled RRs were increased for abdominal wall defects (1.46; 95% CI, 0.89-2.38), tetralogy of Fallot (1.45; 95% CI, 0.86-2.46), and neural tube defects (1.62; 95% CI, 0.96-2.74), these associations were imprecisely estimated, driven by the Medicaid cohort and not replicated in the MarketScan cohort. Results were consistent across multiple sensitivity analyses.Conclusions and RelevanceThese findings suggest that Z-drug exposure in the first trimester of pregnancy is not associated with a meaningful elevation in the risk of congenital malformations overall, nor was there a consistent signal observed for organ-specific or uncommon, individual malformations examined.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"24 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1001/jamapsychiatry.2025.3883
Robert H Pietrzak,Ian C Fischer,Brandon Nichter,Irina Esterlis,John H Krystal,Christine Y Moutier,Maria A Oquendo,Dilip V Jeste,Peter Jongho Na
{"title":"Social Determinants of Health and Suicide Risk in US Military Veterans.","authors":"Robert H Pietrzak,Ian C Fischer,Brandon Nichter,Irina Esterlis,John H Krystal,Christine Y Moutier,Maria A Oquendo,Dilip V Jeste,Peter Jongho Na","doi":"10.1001/jamapsychiatry.2025.3883","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.3883","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"84 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1001/jamapsychiatry.2025.4259
David Curtis
{"title":"Restricting Liafensine on the Basis of ANK3 Genotype-More Evidence Needed.","authors":"David Curtis","doi":"10.1001/jamapsychiatry.2025.4259","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.4259","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"1 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：